Health economics in haemophilia: A review from the clinician's perspective

Haemophilia

Volumn 16, Issue SUPPL. 3, 2010, Pages 29-34

  Escobar, M A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Cost utility; Haemophilia; Health economics; Pd APCC; RFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

COST-BENEFIT ANALYSIS; FACTOR VIIA; HEALTH CARE COSTS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS;

EID: 77953501756     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02257.x     Document Type: Review

References (32)

1. WFH Report on the Annual Global Survey 2007. http://www.wfh.org/2/docs/Publications/Statistics/2007-Survey-Report.pdf, Available at Accessed November 13, 2009
2. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000, 96:1698-702.
3. WFH Fact Sheet 1. 2004, http://www.wfh.org/2/7/7_0_Publications.htm, Available at Accessed November 13, 2009
4. WFH Fact Sheet 4. 2005, http://www.wfh.org/2/7/7_0_Publications.htm, Available at Accessed November 13, 2009
5. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998, 63:7-10.
6. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000, 11(Suppl. 1):S45-9.
7. Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998, 9(Suppl. 1):S93-5.
8. Shapiro A. Inhibitor treatment: state of the art. Semin Hematol 2001, 38(Suppl. 12):26-34.
9. Ng HJ, Lee HJ. Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients. Vasc Health Risk Manag 2006, 2:433-40.
10. Salaj P, Brabec P, Penka M. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009, 15:752-9.
11. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol 1998, 63(Suppl.):24-27.
12. Hay CR, Baglin TP, Collins PW, Hill FGH, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 2000, 111:78-90.
13. Honda K, Nagao T, Kamiya T. Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors [article in Japanese]. Rinsho Ketsueki 1998, 39:416-21.
14. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003, 102:2358-63.
15. Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006, 2(Suppl. 4):S8-13.
16. Knight C, Danø AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 2009, 15:405-19.
17. Lyseng-Williamson KA, Plosker GL. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics 2007, 25:1007-29.
18. Knight C, Paisley S, Wight J, Lloyd-Jones M. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003, 9:521-40.
19. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001, 7:279-85.
20. Chung K, Berger A, Edelsberg J, Neufeld E, Oster G. Cost-effectiveness of FEIBA vs. NovoSeven as initial therapy for the treatment of mild-to-moderate bleeds in hemophilia patients with inhibitors [abstract]. Haemophilia 2004, 10(Suppl. 3):29-33.
21. Huth-Kühne A, Lages P, Zimmermann R. The impact of rebleeds in cost modelling of treatment strategies in patients with haemophilia A and inhibitors [abstract]. Blood 2006, 108. Abstract 4046
22. Dundar S, Zülfikar B, Kavakli K. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005, 8:46-54.
23. Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006, 22:23-31.
24. Odeyemi IA, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002, 5:119-33.
25. Odeyemi I, Guest J. Modelling the economic impact of recombinant activated factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX at a comprehensive care centre in the UK. J Med Econ 2002, 5:51-64.
26. Ozelo MC, Villaça PR, De Almeida JO. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007, 13:462-9.
27. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005, 11:261-9.
28. Steen Carlsson K, Astermark J, Donfield S, Berntorp E. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008, 99:1060-7.
29. You CW, Lee SY, Park SK. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. Haemophilia 2009, 15:217-26.
30. Waters E, Salmon L, Wake M, Hesketh K, Wright M. The Child Health Questionnaire in Australia: reliability, validity and population means. Aust N Z J Public Health 2000, 24:207-10.
31. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1994, 16:655-62.
32. Astermark J, Donfield SM, DiMichele DM. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-51.